Lufotrelvir (PF-07304814) is a 3CL protease inhibitor targeting SARS-CoV-2, designed for COVID-19 research. It exhibits broad-spectrum activity against related coronaviruses in vitro and has demonstrated antiviral efficacy in animal models, supporting its investigation for novel coronavirus infections.